A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials-Reference-Cited by-同舟云学术

A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials

Published:2020-12 Issue:12 Volume:31 Page:1704-1708
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Amiri-Kordestani L.,Xie D.,Tolaney S.M.,Bloomquist E.,Tang S.,Ibrahim A.,Goldberg K.B.,Theoret M.R.,Pazdur R.,Sridhara R.,Winer E.P.,Beaver J.A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference12 articles.

1. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;N Engl J Med,2011

2. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

3. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Engl J Med,2005

4. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer;Tolaney;N Engl J Med,2015

5. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial);Bellon;Breast Cancer Res Treat,2019

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accrual and statistical power failure in published adjuvant phase III oncology trials: a comprehensive analysis from 2013 to 2023;ESMO Open;2024-07

2. The safety, feasibility and oncological outcomes of laparoscopic completion total gastrectomy for remnant gastric cancer: a prospective study with 3-year follow-up (FUGES-004 study);International Journal of Surgery;2024-04-09

3. Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab;Critical Reviews in Oncology/Hematology;2023-10

4. A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer;Current Oncology;2023-08-04

5. FDA Oncology Center of Excellence Crowdsourcing Initiative: Outreach to the Scientific Community to Identify Research Questions for Pooled Analyses of Oncology Clinical Trial Data;Clinical Cancer Research;2023-04-03